Methods of using regenerative cells to promote wound healing

• US 20050048034A1
• Filed: 07/01/2004
• Published: 03/03/2005
• Est. Priority Date: 12/07/2001
• Status: Active Grant

• Current Assignee: Lorem Vascular Pte. Ltd.
• Original Assignee: Cytori Therapeutics Incorporated
• Inventors: Fraser, John K., Hedrick, Marc H., Daniels, Eric
• Granted Patent: US 8,105,580 B2
• Time in Patent Office: Days
• US Class Current: 424/93.700
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 35/12 Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells vaccines or medicinal preparations containing antigens or antibodies A61K39/00
• CPC Class Codes: A61K 35/28 Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
• CPC Class Codes: A61K 35/35 Fat tissue; Adipocytes; Stromal cells; Connective tissues adipose-derived stem cells A61K35/28; collagen A61K38/39
• CPC Class Codes: A61K 35/36 Skin; Hair; Nails; Sebaceous glands; Cerumen; Epidermis; Epithelial cells; Keratinocytes; Langerhans cells; Ectodermal cells islets of Langerhans A61K35/39
• CPC Class Codes: A61K 35/44 Vessels; Vascular smooth muscle cells; Endothelial cells; Endothelial progenitor cells
• CPC Class Codes: A61K 38/1866 Vascular endothelial growth factor [VEGF]
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61K 9/0014 Skin, i.e. galenical aspects of topical compositions non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00
• CPC Class Codes: A61L 15/40 containing ingredients of undetermined constitution or reaction products thereof , e.g. plant or animal extracts
• CPC Class Codes: A61L 15/44 Medicaments
• CPC Class Codes: A61L 2300/412 Tissue-regenerating or healing or proliferative agents
• CPC Class Codes: A61L 2300/64 Animal cells
• CPC Class Codes: A61L 27/3604 characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
• CPC Class Codes: A61L 27/3834 Cells able to produce different cell types, e.g. hematopoietic stem cells, mesenchymal stem cells, marrow stromal cells, embryonic stem cells
• CPC Class Codes: A61L 27/54 Biologically active materials, e.g. therapeutic substances A61L27/227 takes precedence
• CPC Class Codes: A61L 27/56 Porous materials, e.g. foams or sponges
• CPC Class Codes: A61P 1/00 Drugs for disorders of the alimentary tract or the digestive system
• CPC Class Codes: A61P 1/16 for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• CPC Class Codes: A61P 11/00 Drugs for disorders of the respiratory system
• CPC Class Codes: A61P 13/12 : of the kidneys
• CPC Class Codes: A61P 17/00 : Drugs for dermatological disorders
• CPC Class Codes: A61P 17/02 : for treating wounds, ulcers, burns, scars, keloids, or the like
• CPC Class Codes: A61P 19/00 : Drugs for skeletal disorders
• CPC Class Codes: A61P 19/02 : for joint disorders, e.g. arthritis, arthrosis
• CPC Class Codes: A61P 21/00 : Drugs for disorders of the muscular or neuromuscular system
• CPC Class Codes: A61P 25/00 : Drugs for disorders of the nervous system
• CPC Class Codes: A61P 27/02 : Ophthalmic agents
• CPC Class Codes: A61P 3/00 : Drugs for disorders of the metabolism of the blood or the extracellular fluid A61P7/00
• CPC Class Codes: A61P 3/10 : for hyperglycaemia, e.g. antidiabetics
• CPC Class Codes: A61P 37/06 : Immunosuppressants, e.g. drugs for graft rejection
• CPC Class Codes: A61P 9/00 : Drugs for disorders of the cardiovascular system
• CPC Class Codes: A61P 9/10 : for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• CPC Class Codes: C12N 2506/1384 : from adipose-derived stem cells [ADSC], from adipose stromal stem cells
• CPC Class Codes: C12N 5/0667 : Adipose-derived stem cells [ADSC]; Adipose stromal stem cells
• CPC Class Codes: C12N 5/069 : Vascular Endothelial cells

Abstract

Cells present in adipose tissue are used to promote wound healing in a patient. Methods of treating patients include processing adipose tissue to deliver a concentrated amount of regenerative cells obtained from the adipose tissue to a patient. The methods may be practiced in a closed system so that the regenerative cells are not exposed to an external environment prior to being administered to a patient. Accordingly, in a preferred method, cells present in adipose tissue are placed directly into a recipient along with such additives necessary to promote, engender or support a therapeutic benefit.

Claims

1. A method for promoting wound healing in a patient, comprising administering to the patient a concentration of regenerative cells.

2. The method of claim 1, wherein the subject is human.

3. The method of claim 1, wherein the regenerative cells are comprised of stem cells.

4. The method of claim 1, wherein the regenerative cells are comprised of progenitor cells.

5. The method of claim 1, wherein the regenerative cells are comprised of a combination of stem cells and progenitor cells.

6. The method of claim 1, wherein the wound healing is promoted by formation of a neodermis at the wound site.

7. The method of claim 1, wherein the wound healing is promoted by re-epithelialization at the wound site.

8. The method of claim 1, wherein the method comprises administering a bolus of the regenerative cells.

9. The method of claim 1, wherein the method comprises administering multiple doses of the regenerative cells.

10. The method of claim 1, wherein the method further comprises administering one or more angiogenic factors.

11. The method of claim 1, wherein the wound is selected from an ischemic ulcer wound, a diabetic wound and a traumatic wound.

12. The method of claim 1, wherein the wherein the method further comprises administering one or more immunosuppressive drugs.

13. The method of claim 1, wherein the regenerative cells are administered via a subcutaneous, dermal or intramuscular administration route.

14. The method of claim 1, wherein the method further comprises administering the regenerative cells to the patient'"'"'s vasculature.

15. The method of claim 1, wherein the regenerative cells are grown in cell culture prior to being administered to the patient.

16. The method of claim 15, wherein the regenerative cells are grown in culture conditions that promote differentiation towards an epithelial phenotype.

17. The method of claim 15, wherein the cell culture conditions promote differentiation towards an endothelial phenotype.

18. The method of claim 15, wherein the cell culture is performed on a scaffold material to generate a two or three dimensional construct that can be placed on or within the patient.

19. The method of claim 18, wherein the scaffold material is resorbable in vivo.

20. The method of claim 1, wherein the regenerative cells are modified by gene transfer such that expression of one or more genes in the modified regenerative cells is altered.

21. The method of claim 20, wherein the modification results in alteration of the level of angiogenesis in the subject.

22. The method of claim 20, wherein the modification results in alteration of the level of epithelialization in the subject.

23. The method of claim 20, wherein the modification results in alteration of the level of MIP-1 alpha, RANTES, MCP-1, MIG, TARC, MIP-2, KC and TRIP, or any combinations thereof.

24. The method of claim 20, wherein the modification results in alteration of the homing properties of the regenerative cells.

25. A method for promoting wound healing in a patient, comprising administering to the patient a concentration of adipose tissue derived regenerative cells, wherein the composition is administered to the same subject from which the adipose tissue was originally harvested.

26. A method for acceleration of hair re-growth at a wound site, comprising administering a concentration of regenerative cells at the wound site.

27. A method for promoting collagen secretion at a wound site, comprising administering a concentration of regenerative cells at the wound site.

28. The method of claim 27, wherein the regenerative cells are grown in cell culture prior to being administered to the patient.